Virus nanoparticle intratumoral vaccines for HER2⁺ malignancies.

ABSTRACT: Our laboratory specializes in the intratumoral (i.t.) delivery of virus nanoparticles (VNPs) that activate immune cells and modulate the tumor microenvironment (TME). For this study, we conjugated the CH401 peptide-containing B-cell, helper T-cell, and cytotoxic T-cell epitopes of HER2-to the plant cowpea mosaic virus (CPMV) and bacteriophage Qβ to develop vaccines for HER2⁺ cancer. In vivo studies confirmed that the CPMV_CH401 i.t. therapeutic vaccine candidate was successful in CT26-HER2 and MC38-HER2 tumor models through the induction of IgG2a antibodies, upregulation of Th1 cytokines, and activation of Th1 cells. On the other hand, the Qβ_CH401 i.t. therapeutic vaccine candidate induced IgG1 antibodies and a Th1/2 balanced response, which did not result i

SUBMITTER: Moreno-Gonzalez MA 

PROVIDER: S-EPMC12710919 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature